Cancer du testicule: particularités cliniques et limites thérapeutiques en milieu hospitalier urologique au Sénégal

Kane, R.; Zakou, A.R.H.; Diao, Bo; Ndiaye, A.; Thiam, Amath; Sow, Yaya; Ondo, Cyrille Zé; Fall, B.; Diagne, B.A.

doi:10.1016/j.afju.2014.04.003

Cited by 3 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The publications from Nigeria and Tanzania utilized the Royal Marsden Staging System with an average of 36.2% of patients presenting with stage IV testicular cancer. Germ Cell Tumor accounted for 84.2% of all 11,12,15 The average 5-year survival was 34.3% from four reviews. [10][11][12]15 Discussion and Recommendation…”

Section: Evidence Synthesismentioning

confidence: 99%

“…Over an average of 15.8 years, 256 patients were management for TC from 8 publications in the Sub-Saharan region. [10][11][12][13][14][15][16][17] These were all retrospective studies with some limitations in diagnostic imaging, staging and treatment protocols. However, based on the AUA, EAU, CUA, NCCN guidelines, 1,3,8 major recommendations were summarized against the available publications in the region.…”

Section: Evidence Synthesismentioning

confidence: 99%

“…A publication by Kane et al 11 from Senegal involving 17 patients over 15 years reported full clinical staging with the use of trans-scrotal ultrasound, abdominopelvic CT-scan and serum tumor marker thus the TNM-S. Most other studies in the review from the Sub-Saharan region were limited by either the study design, the absence of CT-scan 12,15 or serum tumor marker testing.…”

Section: Evidence Synthesismentioning

confidence: 99%

“…Amongst the 256 patients in the review of 8 Sub-Saharan publications with testicular cancer, germ cell tumor was the commonest 84.2% with non-seminomatous predominance. A few studies from the review [10][11][12]15 outlined their various treatment modalities which included adjuvant chemotherapy (most common treatment), chemotherapy + radiotherapy, orchidectomy + Chemotherapy + radiotherapy, orchidectomy alone, chemotherapy alone or radiotherapy alone. No retroperitoneal lymph node dissection was performed as most patients decline the procedure 10,11,14 which is much lower than the poor prognosis NSGCT as stratified by the IGCCCG risk classification (45% to 50%).…”

Section: Management Of Metastatic Disease (Stage Iic and Iii) (2)mentioning

confidence: 99%

“…The average 5-year overall survival from 4 reports in the review of sub-Saharan literature was 34.3%. [10][11][12]15 Cancer research and management remain a challenge in most developing nations as diagnostics and proper documentation make retrospective studies difficult to conduct. The need for improving oncological care and creating a cancer registry cannot be emphasized more.…”

Section: Management Of Metastatic Disease (Stage Iic and Iii) (2)mentioning

confidence: 99%

See 4 more Smart Citations

<p>Review of Testicular Tumor: Diagnostic Approach and Management Outcome in Africa</p>

Cassell¹,

Jalloh²,

Yunusa³

et al. 2020

RRU

View full text Add to dashboard Cite

Testicular cancer is a common malignancy in young males with higher incidence in developed nations but with the lowest incidence in Africa (0.3-0.6/100 000). Ironically, the global testicular cancer mortality rate has shown a reverse trend to its incidence with higher rates in low-and middle-income countries (0.5 per 100 000) than in high-income countries. Data from GLOBOCAN 2008 have shown relatively high mortality rates in sub-Saharan countries like Mali, Ethiopia, Niger and Malawi. The prognosis of testicular tumor is good with remarkable chemosensitivity to cisplatin-based regimen. Early diagnosis, careful staging and a multidisciplinary management approach is crucial to achieve this optimal result. These results are achievable in the sub-Saharan region if the relevant resources are appropriated for cancer care and clinical guidelines are formulated in a regional context.

show abstract

Section: Evidence Synthesismentioning

confidence: 99%

Section: Evidence Synthesismentioning

confidence: 99%

Section: Evidence Synthesismentioning

confidence: 99%

Section: Management Of Metastatic Disease (Stage Iic and Iii) (2)mentioning

confidence: 99%

Section: Management Of Metastatic Disease (Stage Iic and Iii) (2)mentioning

confidence: 99%

See 3 more Smart Citations

<p>Review of Testicular Tumor: Diagnostic Approach and Management Outcome in Africa</p>

Cassell¹,

Jalloh²,

Yunusa³

et al. 2020

RRU

View full text Add to dashboard Cite

show abstract

Occlusive Syndrome Revealing a Nonseminoma Germ Cell Tumor Metastatic Testicular

N¹,

Kane²,

Diallo³

et al. 2016

OJU

Self Cite

View full text Add to dashboard Cite

Testicular cancer is rare. The authors report the case of a young Senegalese 21, who has consulted for an occlusive syndrome evolving for 48 hours that prompted his hospitalization. Note that the patient has consulted several times to persistent inguinal scrotal pain, a big right purse with chronic analgesic requirements and anti-inflammatory. Occlusive before this table, abdominal pelvic CT was performed and highlighted the presence of lung metastases, a large pelvic lymph node casting bridging the inter vesico-rectal space and responsible for extrinsic compression of the small intestine, lymph node inter casting aorto-cellar and latero aortic liver and multiple secondary locations. Faced with this bundle of arguments, clinical and laboratory, metastatic testicular tumor was raised and measured tumor markers. A right orchiectomy by inguinal was made with histology: A non-seminomatous germ cell tumor stage III. After orchiectomy germinal markers were still high and there was the problem of persistent occlusive syndrome despite resuscitation. A chemotherapy regimen was initiated with 4 cycles of chemotherapy according to the protocol BEP (bleomycin, etoposide, cisplatin). A significant regression of occlusive syndrome with a decline in clinical symptoms was noted. The revaluation at 3 months, 6 months and 1 year were highlighted: A normal clinical examination associated with a persistent correction rate of germline markers and lack of active lesion at thoraco-abdominopelvic CT.

show abstract

Management of Testicular Cancers in Brazzaville

Banga-Mouss,

Nyanga,

Epala

et al. 2024

OJU

View full text Add to dashboard Cite

Introduction: Testicular cancer accounts for 5% of urological tumors, predominantly affecting young men. The aim of our study was to report the diagnostic and evolutionary aspects of testicular cancer cases treated in our center. Patients and Methods: A retrospective study conducted over a 15-year period involving 12 patients treated for testicular cancer at the University Hospital of Brazzaville. Results: The median age was 31 years (range 11 to 49 years), with a median consultation delay of 10.6 months (range 3 to 27 months). Scrotal mass was the most common reason for consultation. Cancer was bilateral in two patients. Two patients were admitted with metastatic disease. Histopathological examination favored germ cell tumors in 7 cases, two cases of non-Hodgkin's malignant lymphoma, and one case of epididymo-testicular adenocarcinoma. Adjuvant chemotherapy resulted in complete remission in patients with germ cell tumors. However, neoadjuvant chemotherapy was not effective in patients admitted with advanced-stage disease. Conclusion: Testicular cancer is a rare condition that is curable in the majority of cases, but its management is often complicated in our setting due to delayed diagnosis caused by taboos surrounding genital organ pathologies.

show abstract

Cancer du testicule: particularités cliniques et limites thérapeutiques en milieu hospitalier urologique au Sénégal

Cited by 3 publications

References 10 publications

<p>Review of Testicular Tumor: Diagnostic Approach and Management Outcome in Africa</p>

<p>Review of Testicular Tumor: Diagnostic Approach and Management Outcome in Africa</p>

Occlusive Syndrome Revealing a Nonseminoma Germ Cell Tumor Metastatic Testicular

Management of Testicular Cancers in Brazzaville

Contact Info

Product

Resources

About